Fondu is a fun, easy way to share bite-size restaurant reviews with your friends for the iPhone. It's free and perfect whether you're telling your friends what your favorite spots are, recommending what dishes to order, or seeing what a friend thought of a place. Fondu is co-founded by Gauri Manglik (NYU '10), Orion Burt (NYU '12) and Mike Lewis (RIT '08) and first started out of Lawrence Lenihan's "Ready, Fire!, Aim" class at NYU. Fondu's investors include ENIAC Ventures, Jim Pallotta, Zach Arons, Harbor Road Ventures, the NYU Innovation Venture Fund, among others. (Acquired by AirBnB.)
numberFire is the next generation of sports analytics, combining proprietary metrics to better assess historical player and team performance with groundbreaking algorithmics to project future efficacy. Co-founders Nik Bonaddio met Sean Weinstock, an NYU Law student, met when Nik brought an early iteration of numberFire to InSITE, a group that combines NYU and Columbia JD and MBA students to advise entrepreneurs on their venture pitches. Together, the two made the project into a company, participating in the ER Accelerator program. numberFire's investors include RRE, David Tisch's Box Group, Penny Black, and the NYU Innovation Venture Fund, among others.
Tagasauris provides a game-changing approach to metadata creation. The Tagasauris platform combines human and machine intelligence to boost ROI, quality, and speed, leading to new opportunities for engagement. Tagasauris is the result of a collaboration between NYU Stern Professor Panos Ipeirotis (Chief Scientist) and vetern entrepreneur Todd Carter (CEO). Tagasauris' investors included Mike Priest and the NYU Innovation Venture Fund, among others.
Vengo builds and operates small, cloud-based vending machines that combine interactive digital media with point-of-purchase. The impulse purchase at the grocery checkout line is down by 1/3 and brands are seeking new platforms to interact and engage with consumers. Vengo creates retail in new locations through a direct, interactive sales and media channel. Further, Vengo leverages this platform to provide brands the data and information to help drive informed decisions.
TB Biosciences is creating the world’s first point-of-care (POC) tuberculosis (TB) diagnostic test to meet criteria set forth by the World Health Organization (WHO). TB Biosciences’ preliminary performance data meets all WHO specifications and demonstrates sensitivity greater than 90%. This rapid, accurate, and affordable test is based on 20 years of research under the scientific leadership of NYU Professor Suman Laal. Dr. Laal and her team have joined diagnostic expert and serial entrepreneur Dr. Sam Niedbala to commercialize the test. TB Biosciences investors include Originate Ventures, Ben Franklin Technology Partners, and NYU Innovation Venture Fund.
Orca Pharmaceuticals is developing an oral therapeutic agent to treat autoimmune diseases such as psoriasis by targeting the RORγt receptor. The company, located in Oxford UK, is based on technology developed by Dr. Dan Littman from New York University, the first scientist to highlight the essential role of RORγt in autoimmune disease. The startup was formed in collaboration with founders Dr. Michael Hunter and Dr. Roy Pettipher, the heads of Discovery and Pharmacology of Oxagen Ltd. Orca Pharmaceuticals investors include BioMotiv, a Cleveland, Ohio based therapeutics accelerator affiliated with The Harrington Project, and the NYU Innovation Venture Fund.
BioDigital has developed the BioDigital Human, a platform that reveals the body in interactive 3D. BioDigital Human enables users to explore anatomy and disease, create and share custom views, and learn about personal health. NYU has helped the company pilot the technology at its medical school. Investors include FirstMark Capital and the NYU Innovation Venture Fund at New York University.